Top-Rated StocksTop-RatedNASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $126.24 +1.07 (+0.85%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About TransMedics Group Stock (NASDAQ:TMDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TransMedics Group alerts:Sign Up Key Stats Today's Range$126.13▼$134.2150-Day Range$118.66▼$176.1152-Week Range$36.42▼$177.37Volume4.40 million shsAverage Volume860,740 shsMarket Capitalization$4.21 billionP/E Ratio3,156.00Dividend YieldN/APrice Target$174.30Consensus RatingBuy Company OverviewTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Read More… Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. TransMedics Group Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks77th Percentile Overall ScoreTMDX MarketRank™: TransMedics Group scored higher than 77% of companies evaluated by MarketBeat, and ranked 300th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTransMedics Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTransMedics Group has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TransMedics Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth50.82% Earnings GrowthEarnings for TransMedics Group are expected to grow by 50.82% in the coming year, from $1.22 to $1.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is 3,156.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 133.78.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is 3,156.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 138.01.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 30.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.30% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in TransMedics Group has recently increased by 6.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.30% of the outstanding shares of TransMedics Group have been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in TransMedics Group has recently increased by 6.98%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment0.03 News SentimentTransMedics Group has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for TransMedics Group this week, compared to 7 articles on an average week.Search Interest23 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 109% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,981,907.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address TMDX Stock News HeadlinesWaleed H. Hassanein Sells 8,625 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockOctober 19, 2024 | insidertrades.comTamer I. Khayal Sells 2,958 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockOctober 4, 2024 | insidertrades.comUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 29, 2024 | Porter & Company (Ad)TransMedics Misses on Earnings, RevenueOctober 28 at 11:45 PM | fool.comTransMedics Group options imply 19.0% move in share price post-earningsOctober 28 at 11:45 PM | markets.businessinsider.comINVESTIGATION ALERT (NASDAQ:TMDX): DiCello Levitt LLP Is Investigating Investor Claims Against TransMedics Group, Inc. and Encourages TMDX Investors with Losses to Contact the FirmOctober 28 at 10:29 PM | globenewswire.comTransMedics Group Stock Sinks On Q3 Earnings: The DetailsOctober 28 at 6:30 PM | benzinga.comTransMedics Reports Third Quarter 2024 Financial ResultsOctober 28 at 4:05 PM | prnewswire.comSee More Headlines TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $78.93 at the beginning of the year. Since then, TMDX stock has increased by 59.9% and is now trading at $126.24. View the best growth stocks for 2024 here. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) issued its earnings results on Wednesday, July, 31st. The company reported $0.35 EPS for the quarter, beating the consensus estimate of $0.21 by $0.14. The business's revenue for the quarter was up 117.7% compared to the same quarter last year. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? Top institutional investors of TransMedics Group include Allspring Global Investments Holdings LLC (1.82%), New York State Common Retirement Fund (0.30%), Handelsbanken Fonder AB (0.19%) and Moody Aldrich Partners LLC (0.08%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Miriam Provost, Stephen Gordon, Nicholas Corcoran, Tamer I Khayal, John F Carey, David Weill, Anil P Ranganath, Edward M Basile, Stephanie Lovell, Laura Damme and Edwin M Kania Jr. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Broadcom (AVGO), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings7/31/2024Today10/28/2024Next Earnings (Confirmed)10/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:TMDX CUSIPN/A CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$174.30 High Stock Price Target$208.00 Low Stock Price Target$127.00 Potential Upside/Downside+38.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio3,156.00 Forward P/E Ratio103.48 P/E GrowthN/ANet Income$-25,030,000.00 Net Margins0.84% Pretax Margin0.41% Return on Equity15.98% Return on Assets3.41% Debt Debt-to-Equity Ratio2.67 Current Ratio9.37 Quick Ratio8.48 Sales & Book Value Annual Sales$241.62 million Price / Sales17.43 Cash Flow$0.14 per share Price / Cash Flow879.39 Book Value$4.20 per share Price / Book30.06Miscellaneous Outstanding Shares33,360,000Free Float31,024,000Market Cap$4.21 billion OptionableOptionable Beta1.99 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:TMDX) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.